Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:20 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 9,942 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Clear all
Completed Phase 1 Interventional

A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects

NCT00000792
View directory record Official record
Conditions
HIV Infections
Interventions
Hypericin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 3, 2026, 7:20 PM EST
Not listed No phase listed Observational

Clinical Validation of CD Diagnostics Synovasure PJI ELISA Test and Synovasure PJI Lateral Flow Test for Detection of Periprosthetic Joint Infection in Synovial Fluid

NCT02868736
View directory record Official record
Conditions
Periprosthetic Joint Infection
Interventions
Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test
Device
Lead sponsor
CD Diagnostics
Industry
Eligibility
22 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Nov 3, 2026, 7:20 PM EST
Completed Phase 3 Interventional Results available

Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis

NCT00076336
View directory record Official record
Conditions
Hepatitis, Hepatitis B, Chronic, Cirrhosis
Interventions
Telbivudine, Lamivudine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2011 · Synced Nov 3, 2026, 7:20 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Human Papillomavirus (HPV) Infection in Pregnancy

NCT00194311
View directory record Official record
Conditions
Papillomavirus Infections, Pregnancy Complications
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Nov 3, 2026, 7:20 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser

NCT03054155
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Alexandrite Laser
Device
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Nov 3, 2026, 7:20 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy

NCT01479478
View directory record Official record
Conditions
Infection, Pregnancy
Interventions
Placebo, Probiotic dietary supplement
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
3
States / cities
Aptos, California • Santa Cruz, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Nov 3, 2026, 7:20 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults

NCT00094718
View directory record Official record
Conditions
West Nile Fever Encephalitis
Interventions
WN/DEN4-3'delta30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Nov 3, 2026, 7:20 PM EST
Recruiting Not applicable Interventional

Enhanced Nutritional Optimization in LVAD Trial

NCT05655910
View directory record Official record
Conditions
Heart Failure, Gut Microbiome, Nutritional Deficiency
Interventions
Ensure Surgery Immunonutrition shake
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Nov 3, 2026, 7:20 PM EST
Completed Phase 4 Interventional

A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood

NCT00001317
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
interferon-gamma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 7:20 PM EST
Withdrawn Phase 2 Interventional

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

NCT05701189
View directory record Official record
Conditions
Guillain-Barre Syndrome
Interventions
Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg)
Drug
Lead sponsor
Chafic Karam
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 3, 2026, 7:20 PM EST
Recruiting Phase 3 Interventional

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

NCT05699174
View directory record Official record
Conditions
Infections, Infected Wound, Nonunion of Fracture, Injury Leg, Amputation, Internal Fixation; Complications, Infection or Inflammation, Fracture, Lower Extremity Fracture, Antibiotic Side Effect
Interventions
Standard of Care PO (oral) antibiotics, Standard of Care Intravenous (IV) antibiotics
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Minneapolis, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 3, 2026, 7:20 PM EST
Completed Phase 3 Interventional

Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir

NCT00002220
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Efavirenz, Levocarnitine, Adefovir dipivoxil
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 7:20 PM EST
Completed Phase 3 Interventional

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

NCT00002359
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
The Immune Response Corporation
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
54
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 7:20 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

NCT00110591
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 140
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Nov 3, 2026, 7:20 PM EST
Completed Not applicable Interventional

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

NCT00000859
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
32
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Nov 3, 2026, 7:20 PM EST
Completed Phase 4 Interventional Results available

Hepatitis C Virus(HCV) Heart and Lung Study

NCT02858180
View directory record Official record
Conditions
Hepatitis C, Chronic, Heart Failure, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Interventions
Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Detroit, Michigan • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Nov 3, 2026, 7:20 PM EST
Completed Phase 2 Interventional

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

NCT00722358
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-650032, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Anaheim, California • Orlando, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Nov 3, 2026, 7:20 PM EST
Withdrawn Phase 3 Interventional

MC RCT - BPO vs Adapalene

NCT05536882
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
Benzoyl peroxide, Adapalene Gel
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Year to 14 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Nov 3, 2026, 7:20 PM EST
Not listed No phase listed Observational

Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV

NCT01709448
View directory record Official record
Conditions
Neoplasms, Squamous Cell, Papillomavirus Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Nov 3, 2026, 7:20 PM EST
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

NCT00325078
View directory record Official record
Conditions
Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Nov 3, 2026, 7:20 PM EST
Terminated Not applicable Interventional Results available

Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)

NCT02503735
View directory record Official record
Conditions
Hepatitis C, Chronic Kidney Disease
Interventions
Sofosbuvir/Ledipasvir FDC
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Nov 3, 2026, 7:20 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Joining Under-connected Networks to Optimize "Salud" (Health) ("JUNTOS")

NCT06432725
View directory record Official record
Conditions
Hiv
Interventions
JUNTOS, Referral Sheet
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 3, 2026, 7:20 PM EST
Active, not recruiting Not applicable Interventional

Autoimmune Intervention Mastery Course Study

NCT05057676
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome, Fibromyalgia, Post Acute Sequelae of COVID-19, Cancer in Remission With Persisting Fatigue
Interventions
Immediate Autoimmune Intervention Mastery Course (AIM), Immediate Question and Answer sessions. (AIM Q and A sessions), Delayed Autoimmune Intervention Mastery Course (delayed AIM course), Delayed AIM Question and Answer sessions
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 3, 2026, 7:20 PM EST
Not yet recruiting Not applicable Interventional

Implementation of an Opt-Out Testing and Rapid Diagnostic Strategy for Syphilis and HIV in Pregnant Patients Presenting to the Emergency Department

NCT07525076
View directory record Official record
Conditions
HIV Infections, Syphilis Infection
Interventions
Chembio HIV/Syphilis rapid Point of Care (POC) test, Laboratory-based HIV and syphilis testing
Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 3, 2026, 7:20 PM EST